Parmax Pharma Gets In-Principle Approval for Share & Warrant Issue

Parmax Pharma Ltd has received 'In-Principle' Approval from BSE Limited for the issuance of equity shares and warrants on a preferential basis. The approval, granted under Regulation 28(1) of SEBI LODR Regulations, permits the issuance of 31,37,586 equity shares at a price of not less than ₹36.50 per share and 21,45,145 warrants convertible into equity shares at a price of not less than ₹36.50 per warrant. This approval is contingent upon compliance with applicable SEBI regulations. The company had previously intimated about this proposed issuance on June 8, 2026.